 Myovant Sciences Ltd NYSE: MYOV received European approval for Orgovyx relugolix, 120 mg for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a 1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback. 